Pure Play Orthobiologics Will Expand US Healthcare Access

Published
07 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
SEK 15.50
8.8% undervalued intrinsic discount
15 Aug
SEK 14.14
Loading
1Y
80.4%
7D
-1.4%

Author's Valuation

SEK 15.5

8.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on08 Aug 25
Fair value Decreased 1.06%

With OssDsign's consensus price target revised lower, primarily driven by a notable drop in its Future P/E from 77.22x to 64.47x, the fair value estimate has decreased from SEK15.67 to SEK14.83. What's in the News An undisclosed buyer acquired an unknown minority stake in OssDsign AB from Karolinska Development AB.

Shared on01 May 25
Fair value Increased 7.31%

Shared on24 Apr 25

AnalystConsensusTarget has increased profit margin from 2.4% to 3.2% and decreased future PE multiple from 208.1x to 161.5x.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 6.81%

AnalystConsensusTarget has decreased profit margin from 9.2% to 2.4% and increased future PE multiple from 61.7x to 208.0x.